Corrigendum to ‘The peptidic GHS-R antagonist [d-Lys3]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity’ [Molecular and Cellular Endocrinology 343 (1–2) (2011) 55–62]

2012 ◽  
Vol 348 (1) ◽  
pp. 344
Author(s):  
L. Maletínská ◽  
R. Matyšková ◽  
J. Maixnerová ◽  
D. Sýkora ◽  
M. Pýchová ◽  
...  
Keyword(s):  
Mouse Model ◽  
Metabolic Abnormalities ◽  
Postmenopausal Obesity ◽  
Cellular Endocrinology

scholarly journals The Peptidic GHS-R antagonist [D-Lys3]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity

2011 ◽  
Vol 343 (1-2) ◽  
pp. 55-62 ◽  
Author(s):  
L. Maletínská ◽  
R. Matyšková ◽  
J. Maixnerová ◽  
D. Sýkora ◽  
M. Pýchová ◽  
...  
Keyword(s):  
Mouse Model ◽  
Metabolic Abnormalities ◽  
Postmenopausal Obesity

scholarly journals Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity

2015 ◽  
Vol 227 (1) ◽  
pp. 25-36 ◽  
Author(s):  
Azusa Sameshima ◽  
Tsutomu Wada ◽  
Tetsuo Ito ◽  
Ayaka Kashimura ◽  
Kanae Sawakawa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Visceral Obesity ◽  
Calorie Intake ◽  
Control Group ◽  
Standard Diet ◽  
Dark Phase ◽  
Therapeutic Effects ◽  
Metabolic Abnormalities ◽  
Postmenopausal Obesity

A decrease in serum estrogen levels in menopause is closely associated with the development of visceral obesity and the onset of type 2 diabetes in women. In the present study, we demonstrated the therapeutic effects of the novel DPP4 inhibitor, teneligliptin, on the features of postmenopausal obesity in mice. In the control group, female C57BL/6 mice were sham-operated and maintained on a standard diet. In the postmenopausal obese group, ovariectomized (OVX) mice were maintained on a high-fat diet, and were referred to as OVX-HF. In the treated group, teneligliptin at 60 mg/kg per day was administrated to OVX-HF, and were referred to as Tene. After a 12-week food challenge, the metabolic phenotypes of these mice were analyzed. Body weight, fat accumulation, and glucose intolerance were greater in OVX-HF than in control, while these abnormalities were markedly improved without alterations in calorie intake in Tene. Teneligliptin effectively ameliorated the characteristics of metabolic abnormalities associated with postmenopausal obesity. Regarding chronic inflammation in visceral adipose tissue, the numbers of F4/80+CD11c+CD206− M1-macrophages in flow cytometry, crown-like structure formation in immunohistochemistry, and proinflammatory cytokine expression were significantly attenuated in Tene. Hepatic steatosis was also markedly improved. Furthermore, decreased energy consumption in the dark and light phases, reduced locomotor activity in the dark phase, and lowered core body temperature in OVX-HF were ameliorated in Tene. Since obesity and reduced energy metabolism are a common physiology of menopause, teneligliptin appears to be beneficial as a treatment for type 2 diabetes in postmenopausal obesity.

Abstract A005: MMP FRET ACPP imaging of mammary tumors in a mouse model of postmenopausal obesity

2013 ◽  
Author(s):  
Jessica L. Crisp ◽  
Elamprakash N. Savariar ◽  
Jonathan P. Hasselmann ◽  
Heekyung Chung ◽  
Roger Y. Tsien ◽  
...  
Keyword(s):  
Mouse Model ◽  
Mammary Tumors ◽  
Postmenopausal Obesity

scholarly journals Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Elisabeth Rossaert ◽  
Eveliina Pollari ◽  
Tom Jaspers ◽  
Lawrence Van Helleputte ◽  
Matthew Jarpe ◽  
...  
Keyword(s):  
Mouse Model ◽  
Histone Acetylation ◽  
Metabolic Abnormalities

scholarly journals Time‐Restricted Feeding Attenuates Breast Cancer Growth in a Mouse Model of Postmenopausal Obesity

2018 ◽  
Vol 32 (S1) ◽  
Author(s):  
Manasi Das ◽  
Emilie Gross ◽  
Deepak Kumar ◽  
Consuelo Sauceda ◽  
Hyun‐Tae Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Cancer Growth ◽  
Restricted Feeding ◽  
Postmenopausal Obesity ◽  
Breast Cancer Growth

Metabolic abnormalities precede pathologic changes in the G93A SOD1 mouse model of ALS

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S64-S64 ◽  
Author(s):  
Jon-Paul P DiMauro ◽  
Lichuan Yang ◽  
Sara W Fuller ◽  
Susan E Browne
Keyword(s):  
Mouse Model ◽  
Metabolic Abnormalities ◽  
G93a Sod1 Mouse ◽  
Sod1 Mouse ◽  
G93a Sod1

scholarly journals Should diabetic women with breast cancer have their own intervention studies?

2011 ◽  
Vol 19 (1) ◽  
pp. C13-C17
Author(s):  
David A Potter ◽  
Douglas Yee ◽  
Zhijun Guo ◽  
Mariangellys Rodriguez
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Tumor Growth ◽  
Calorie Restriction ◽  
Mammary Tumor ◽  
Intervention Studies ◽  
Diabetic Mouse ◽  
Mouse Mammary Tumor ◽  
Mammary Tumor Growth ◽  
Postmenopausal Obesity

This commentary on ‘Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity’ by Nogueiraet al., published in this issue ofEndocrine-Related Cancer, addresses the challenges of translating diet, exercise, and pharmacologic trials in diabetic mouse mammary tumor models to human studies. We propose that trials specifically designed to test such interventions in diabetic women with breast cancer would be valuable and informative.

Subtle neurological and metabolic abnormalities in an Opa1 mouse model of autosomal dominant optic atrophy

2009 ◽  
Vol 220 (2) ◽  
pp. 404-409 ◽  
Author(s):  
Marcel V. Alavi ◽  
Nico Fuhrmann ◽  
Huu Phuc Nguyen ◽  
Patrick Yu-Wai-Man ◽  
Peter Heiduschka ◽  
...  
Keyword(s):  
Mouse Model ◽  
Optic Atrophy ◽  
Autosomal Dominant ◽  
Metabolic Abnormalities ◽  
Autosomal Dominant Optic Atrophy ◽  
Dominant Optic Atrophy
Sign in / Sign up

Export Citation Format

Share Document